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eople  who  inject drugs
he  Global Fund
a  b  s  t  r  a  c  t
Background:  Injecting  drug  use has  been  documented  in 158  countries  and  is  a major  contributor  to
HIV  epidemics.  People  who  inject  drugs  have  poor  and  inequitable  access  to HIV  services.  The  Global
Fund  to  Fight  AIDS, Tuberculosis  and  Malaria  is  the  leading  multilateral  donor  for  HIV programmes  and
encourages  applicants  to include  harm  reduction  interventions  in  their  proposals.  This study  is the  ﬁrst
detailed  analysis  of  Global  Fund  investments  in  harm  reduction  interventions.
Methods: The  full list  of  more  than  1000  Global  Fund  grants  was  analysed  to  identify  HIV  grants  that
contain  activities  for people  who  inject  drugs.  Data  were  collected  from  the  detailed  budgets  agreed
between  the  Global  Fund  and  grant  recipients.  Relevant  budget  lines  were  recorded  and  analysed  in
terms  of the  resources  allocated  to  different  interventions.
Results: 120  grants  from  55  countries  and  territories  contained  activities  for people  who  inject  drugs  worth
a  total  of US$  361  million,  increasing  to US$  430  million  after  projections  were  made  for grants  that  had
yet  to enter  their ﬁnal  phase  of  funding.  Two-thirds  of  the  budgeted  US$  361  million  was  allocated  to
core  harm  reduction  activities  as deﬁned  by the  United  Nations.  Thirty-nine  of the  55  countries  were  in
Eastern  Europe  and  Asia.  Only  three  countries  with  generalised  HIV  epidemics  had  grants  that  included
harm  reduction  activities.
Conclusion: This  study  represents  the most  comprehensive  assessment  of Global  Fund  investments  in
harm  reduction.  This  funding,  while  substantial,  falls  short  of  the  estimated  needs.  Investments  in harm
reduction  must  increase  if  HIV  transmission  among  people  who  inject  drugs  is to  be halved  by 2015.
.ntroduction
Globally, there are an estimated 15.9 million people who  inject
rugs, 3 million of whom are living with HIV (Mathers et al.,
008)—representing a prevalence of around 19 percent among this
opulation. Injecting drug use remains a major contributor to HIV
ransmission, accounting for 10 percent of global infections and
round 30 percent of infections outside of sub-Saharan Africa (Cook
 Kanaef, 2008). It has also been estimated that 10 million people
ho inject drugs have hepatitis C (Nelson et al., 2011). Drug inject-
ng has been formally documented in 158 countries, and 120 of
hem report HIV transmission among this population (Cook, 2010).
nited Nations Member States committed in 2011 to “working
owards reducing transmission of HIV among people who  inject
rugs by 50 percent by 2015” (UN General Assembly, 2011).
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Harm reduction can be broadly deﬁned as “policies, pro-
grammes and practices that aim primarily to reduce the adverse
health, social and economic consequences of the use of legal and
illegal psychoactive drugs without necessarily reducing drug con-
sumption” (International Harm Reduction Association, 2011). In
2009 the World Health Organization (WHO), the Joint United
Nations Programme on HIV/AIDS (UNAIDS) and the United Nations
Ofﬁce on Drugs and Crime (UNODC) endorsed a “comprehensive”
harm reduction package of nine interventions for people who  inject
drugs (Box 1 ). No single intervention alone can prevent or reverse
HIV epidemics among people who inject drugs. However, there is
a “wealth of scientiﬁc evidence supporting the efﬁcacy of these
interventions in preventing the spread of HIV” (WHO, UNODC, &
UNAIDS, 2009). The UNAIDS Strategic Investment Framework –
which aims to support more efﬁcient and effective targeting of
resources for HIV – includes harm reduction for people who inject
drugs as one of the core programme activities that “have a direct
effect on reduction of transmission, morbidity, and mortality from
Open access under CC BY-NC-ND licenseHIV/AIDS, and should be scaled up according”. It also recommends
funding of a series of related “critical enablers” including commu-
nity mobilisation, stigma reduction and human rights advocacy
(Schwartländer et al., 2011). Nonetheless, people who  inject drugs
280 J.  Bridge et al. / International Journal of Drug Policy 23 (2012) 279– 285
Box 1
The  United Nations “comprehensive package”
(WHO,  UNODC, & UNAIDS, 2009)
1. Needle and syringe programmes
2. Opioid  substitution therapy and other drug dependence
treatment
3. HIV testing and counselling
4. Antiretroviral therapy
5. Prevention and treatment of sexually transmitted infections
6. Condom  distribution programmes for people who inject
drugs and their sexual partners
7. Targeted information, education and communication for
people who inject drugs and their sexual partners
8. Vaccination, diagnosis and treatment of viral hepatitis
9. Prevention, diagnosis and treatment of tuberculosis
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Box 2: Calculations used for budget projections (where
required).
Latest grant performance rating Grant renewal amount used for project
budgets where required
A1 (exceeding expectations) or
A2 (meeting expectations)
90%
B1  (adequate performance) 80%
B2 (inadequate performance,
but  demonstrating potential)
60%
C (unacceptable performance) 30%
Note: If a performance rating was  not available, calculations for B1 ratings
were  used as this is the most common rating. More information on Global
Fund  performance ratings is available from http://www.theglobalfund.org/en/
The budget lines for activities that speciﬁcally targeted peo-onsistently have poor and inequitable access to services (Mathers
t al., 2010) and often face stigma, discrimination, marginalisation
nd abuse in every walk of life (Beyrer, Malinowska-Sempruch,
amarulzaman, & Strathdee, 2010).
The Global Fund to Fight AIDS, Tuberculosis and Malaria (Global
und) is a public–private partnership and international ﬁnanc-
ng institution dedicated to attracting and investing additional
esources to tackle the three pandemics. Its model is based on coun-
ry ownership and performance-based funding, which means that
ountries implement programmes based on their own  priorities
nd the Global Fund provides ﬁnancing on the condition that ver-
ﬁable results are achieved. Since its creation in 2002, the Global
und has approved more than 1000 grants worth a total of US$
2.6 billion in 150 countries (Global Fund, 2011a).
The Global Fund Board periodically announces calls for propos-
ls, or ﬁnancing “Rounds”. Eligible countries or regional bodies then
evelop and submit proposals through multisector Country Coordi-
ating Mechanisms. To support the proposal development process,
he Global Fund and a range of partners produce guidance and infor-
ation notes on a range of topics, including harm reduction (Global
und, 2011b). Once submitted, proposals are reviewed by an inde-
endent Technical Review Panel which makes recommendations
o the Global Fund Board. Successful proposals are approved for
wo years (“Phase 1”); after which an in-depth review of progress,
esults and impact is conducted before deciding on continued fund-
ng for the next three years (“Phase 2”). Selected successful grants
n Rounds 1–5 were also then invited to apply for a further six years
f funding (in two periods of three years) through the “Rolling
ontinuation Channel” (although this mechanism has since been
iscontinued).
The Global Fund explicitly supports harm reduction as part of its
ommitment to fund evidence-based, cost-effective interventions.
lthough proposals are country-driven, applicants are strongly
ncouraged to include harm reduction interventions—both in
ommunity and prison settings (Global Fund, 2011b). However,
revious research has shown that a relatively small proportion of
he Global Fund portfolio is directly targeted at most-at-risk pop-
lations such as people who inject drugs, sex workers and men
ho have sex with men  (Global Fund, 2010a; Avdeeva, Lazarus,
bdul Aziz, & Atun, 2011). The Global Fund has previously esti-
ated that around US$ 180 million was invested in harm reduction
n 42 countries between Round 1 (2002) and Round 7 (2007)
Atun & Kazatchkine, 2010). This article employs a more detailed
ethodology to review how much the Global Fund invested in
arm reduction interventions between Round 1 (2002) and Round
 (2009).performancebasedfunding/.
Methods
The Global Fund has ﬁnanced more than 1000 grants. The
full list of grants (Global Fund, 2011c) was  ﬁltered to identify
a sub-set of HIV grants that may  contain harm reduction inter-
ventions. Grants from Round 9 included those created under the
new “single stream of funding” model, whereby multiple grants
to the same recipient are consolidated in order to simplify moni-
toring and grant management (Global Fund, 2011d). The ﬁltering
process was conducted by triangulating several sources of infor-
mation: published estimates of Global Fund investments in harm
reduction (Atun & Kazatchkine, 2010) and most-at-risk popula-
tions (Global Fund, 2010a); advanced searches of the Global Fund
portfolio for grants with the service delivery area “HIV Prevention:
Programmes for speciﬁc groups” (Global Fund, 2011e); the Global
Fund’s internal database of grant performance indicators; searches
for key terms – IDU [injecting drug use], inject, user, harm, needle,
syringe, methadone, buprenorphine and substitution – in proposal
documents available from http://portfolio.theglobalfund.org;  and
veriﬁcations from grant management staff within the Global Fund
Secretariat.
Data were collected from the ﬁnal detailed Phase 1, Phase 2 and
Rolling Continuation Channel budgets that were available by the
end of 2011. These complex documents provide the most detailed
source of ﬁnancial data for a grant – including planned expendi-
tures, staff salaries and procurement costs – and are not publically
available. This elaborate method was selected because the stan-
dard Global Fund ﬁnancial reporting does not accurately capture
investments or expenditures for harm reduction: these interven-
tions are often classiﬁed by different countries under different
headings and cost categories because of their politically sensitive
nature.
For budgets in languages other than English, translation was
facilitated by Global Fund staff. Where required, an online currency
converter (www.xe.com) was  used to convert ﬁgures into US$ using
the historical exchange rate from the grant’s start date.
For  grants that were still in Phase 1 of implementation (or in
the ﬁrst period of Rolling Continuation Channel implementation),
detailed budgets were not yet ﬁnalised for Phase 2 (or the ﬁnal
period of Rolling Continuation Channel implementation). Financial
ﬁgures for the full lifetime of these grants were therefore projected
using existing budget data and the Global Fund’s recommended
grant renewal ranges that are tied to performance ratings. For
example, budget totals for a grant rated ‘B1’ were projected by mul-
tiplying the two-year Phase 1 budget by 1.5 (for the three years in
Phase 2) and then multiplying this amount by 80 percent (Box 2 ).ple who  inject drugs were identiﬁed and recorded. Where one
activity covered several most-at-risk populations the budgeted
amount was divided by the number of target groups. For example,
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Table  1
Countries and territories with HIV grants from the Global Fund that include interventions for people who  inject drugs (Rounds 1–9).
Round 1 (2002) Round 2 (2003) Round 3 (2003) Round 4 (2004) Round 5 (2005) Round 6 (2006) Round 7 (2007) Round 8 (2008) Round 9
(2009)a
Argentina Armenia Algeria Azerbaijan Albania Bangladesh Afghanistan Belarus Azerbaijan
Indonesiac Bangladesh Belarus China Bosnia and
Herzegovina
Bhutanc Cambodia Burundi Bosnia and
Herzegovina
Moldova Bulgaria China Indonesia Mongoliac China India Cape Verde Cambodia
Serbia Croatia Macedonia Russia Montenegro Egypt Kazakhstan Indonesia Georgia
Tajikistan Estonia Myanmar Tajikistan Philippinesc Georgia Kenyac Iran India
Ukraine Georgia Philippines Turkey Russia Jordanc Kosovo Madagascar Indonesia
Viet Nam India  Russia Maldives Kyrgyzstan Mauritius Mexico
Iran Thailand Moldova Macedonia Moldova Moldova
Jordanc Uzbekistan Morocco Mongoliac Paraguay Montenegro
Kazakhstan Paraguayc Nepal Serbia Myanmar
Kyrgyzstan Romania West Bank and
Gaza
Tajikistan Nigeria
Nepalc Serbia Thailand Pakistan
Romania Tajikistan Viet Nam Sri Lanka
Tunisia Viet Nam
Ukraine
Viet  Nam
Zanzibarb
a Round 9 grants include “single stream of funding” grants, where new proposals are consolidated with existing grants to the same recipient in order to simplify the Global
Fund grant architecture (Global Fund, 2011d).
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ab Grants included less than US$ 100,000 per year for people who inject drugs.
c Zanzibar is a semi-autonomous part of the United Republic of Tanzania. For the p
rants separate from Tanzania.
f US$ 200,000 was budgeted for “condoms for sex workers and
eople who inject drugs”, then US$ 100,000 was included in this
nalysis. We  did not attempt to apportion and include budget lines
imed at the general population, nor to apportion and include
ndirect or administrative costs within the budget that were not
xplicitly targeting people who inject drugs.
Highlighted budget lines were categorised according to the
comprehensive package” (Box 1) and other key activities. As
lobal Fund budget documents are complex and not standardised,
ctivities were listed in various different ways. Where necessary,
lariﬁcations were obtained from proposal documents. A random
ample of 12 grants was also cross-checked between researchers,
nd results were compared to detect, record and rectify variations.
mall differences were identiﬁed for some of these grants (with an
verage difference of just 1.14 percent of the budgeted totals), and
ll discrepancies were resolved.
Data collected from the detailed budgets were analysed using
icrosoft Excel 2010. Additional information – including Principal
ecipient details and grant agreement amounts – was  also recorded
rom original proposal documents and the Global Fund website
www.theglobalfund.org).
ig. 1. Budgeted and projected Global Fund investments for people who  inject drugs. No
re consolidated with existing grants to the same recipient in order to simplify the Globaes of the Global Fund, it has its own Country Coordinating Mechanism and receives
Results
Between  Round 1 (2002) and Round 9 (2009), a total of 411
HIV grants in 118 countries and territories were approved by the
Global Fund Board, as well as 13 multicountry HIV grants. After
the systematic ﬁltering process, 120 grants from 55 countries and
territories were found to incorporate speciﬁc activities for people
who inject drugs (Table 1). Sixty-six (55 percent) of these grants
were managed by governmental bodies, 28 (23 percent) by civil
society organisations, seven (6 percent) by private sector recipients,
and the remaining 19 (16 percent) by multilateral agencies such as
the United Nations Development Programme.
The ﬁnal, detailed budgets from these grants contained US$
361 million for activities targeting people who inject drugs. When
projections were made for grants that had yet to enter their ﬁnal
stages of implementation, the total investment for people who
inject drugs amounted to US$ 430 million.Of  the 55 countries and territories, 22 were from the Global
Fund’s Eastern Europe and Central Asia Region, nine from its South
and West Asia Region, and eight from its East Asia and Paciﬁc
Region. Only three countries with generalised HIV epidemics were
te: Round 9 grants include “single stream of funding” grants, where new proposals
l Fund grant architecture (Global Fund, 2011d).
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terventions and cost categories. Note: Percentages are rounded.
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Table 2
Distribution of Global Fund investments for major interventions and cost categories
(US$  millions).
Intervention Total budgeted investment
(Rounds  1–9)a
Needle and syringe programmes 76.6
Opioid substitution therapy 56.3
HIV testing and counselling 13.8
Antiretroviral therapy 16.3
Prevention and treatment of sexually transmitted
infections
7.0
Condom distribution programmes 20.0
Targeted information, education and
communication
44.4
Vaccination, diagnosis and treatment of viral
hepatitis
2.2
Prevention, diagnosis and treatment of
tuberculosis
3.2
Development of supportive environments 15.1
Monitoring and evaluation 17.5
Programme management and overheads 49.4
Psychosocial or legal support 14.5
Training and capacity building 9.9
Drug detention centres 5.1
Otherb 9.7
Total budgeted US$ 361 million
Note: Figures are rounded.
a Round 9 includes “single stream of funding” grants, where new proposals areFig. 2. Distribution of Global Fund investments for major in
ncluded. The majority (US$ 263 million; 61 percent) of the US$
30 million projected investment was for Eastern Europe and Cen-
ral Asia. Latin America, the Caribbean, Africa and the Middle East
ollectively accounted for just 5 percent.
Fig. 1 shows the distribution of investments across the nine
unding “Rounds”, with an upward trend since Round 7 (2007). The
udgeted and projected totals were US$ 16 million for Round 1, US$
8 million for Round 2, US$ 55 million for Round 3, US$ 31 million
or Round 4, US$ 18 million for Round 5, US$ 89 million for Round
, US$ 37 million for Round 7, US$ 45 million for Round 8, and US$
1 million for Round 9. The ﬁgure for Round 6 includes two par-
icularly large grants for Ukraine with a combined total of US$
9 million for people who inject drugs.
A  number of Global Fund grants were almost entirely dedicated
o people who inject drugs: including India (Round 9), Pakistan
Round 9), the Russian Federation (Round 5) and Thailand (Rounds
 and 8). By contrast, some of the 120 grants had less than 1 percent
f their overall value allocated for people who inject drugs.
Table  2 and Fig. 2 show how the budget lines targeting peo-
le who inject drugs were allocated between key interventions. Of
he total budgeted funding, 66 percent was allocated to the nine
nterventions that comprise the United Nations’ “comprehensive
ackage” (Box 1). Of these, the interventions with the largest pro-
ortions of funding were needle and syringe programmes, opioid
ubstitution therapy, and information, education and communica-
ion (Fig. 2). Overall, 43 countries and territories had grant budgets
hat included needle and syringe programme activities, and 33 had
rant budgets that included opioid substitution therapy activities.
kraine was the only country that included all nine components of
he “comprehensive package” in their grants.
For all grants, programme management and overheads repre-
ented the largest cost category outside of the “comprehensive
ackage” (Table 2). The budget analysis also showed that three
consolidated  with existing grants to the same recipient in order to simplify the
Global Fund grant architecture (Global Fund, 2011d).
b “Other” activities include, for example, nutritional support, primary care and
ﬁrst  aid, and the prevention of mother-to-child HIV transmission.
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ountries (Cambodia, China and Viet Nam) incorporated activities
elated to compulsory drug detention centres.
iscussion
The results presented in this study conﬁrm earlier ﬁndings that
he Global Fund is a leading source of international support for
arm reduction programmes. Through 120 grants in 55 countries
etween Round 1 (2002) and Round 9 (2009), US$ 361 million
as budgeted for activities for people who inject drugs. This was
rojected to increase to US$ 430 million during the full lifetimes
f these grants. The only previously published estimate of Global
und investments in harm reduction was US$ 180 million between
ounds 1 (2002) and 7 (2007)—or an average of US$ 25.7 million
er Round (Atun & Kazatchkine, 2010). The total presented in this
nalysis represents an average of US$ 48 million budgeted and pro-
ected per Round, and there was an upward trend between Rounds
 and 9.
Nonetheless, more than half of the countries with HIV grants
pproved between Rounds 1 and 9 did not include harm reduc-
ion activities in their budgets. In particular, only three African
ountries with generalised HIV epidemics were included in this
nalysis – Burundi, Kenya and Nigeria – despite injecting drug use
eing a major issue in these epidemiological settings as well as in
ountries with concentrated epidemics (Reid, 2009; WHO, 2011).
revious reports found that, in 2006, no funds were allocated for
his population in countries with generalised epidemics (Global
IV Prevention Working Group, 2009)—highlighting the need for
reater technical support, advocacy and political commitments in
hese settings.
Around 95 percent of the budgeted and projected investments
US$ 408 million) was for Eastern Europe and Asia, where HIV
pidemics are predominantly concentrated among most-at-risk
opulations. In sub-Saharan Africa, only Madagascar and Mauritius
ere funding needle and syringe programmes through Global Fund
upport, and only Mauritius was funding opioid substitution ther-
py.
Of the budgeted US$ 361 million, the majority (66 percent) was
armarked for the nine components of the “comprehensive pack-
ge” (Box 1)—including US$ 76.6 million for needle and syringe
rogrammes, and US$ 56.3 million for opioid substitution pro-
rammes. This is in line with the Global Fund’s commitment to
unding proven, cost-effective interventions. These core interven-
ions were included in grant budgets in most countries, but only
kraine appeared to include the complete package through its
lobal Fund grants.
Some  interventions appeared to receive relatively little fund-
ng speciﬁcally for people who inject drugs – such as HIV testing
nd counselling (US$ 13.8 million), and interventions for viral hep-
titis (US$ 2.2 million) and tuberculosis (US$ 3.2 million). This
ay reﬂect the decision to only include budget lines that explic-
tly identiﬁed people who inject drugs as a target group. While
his approach minimises the incorrect inclusion of activities, it
xcludes population-level activities (such as testing and coun-
elling) that may  also conceivably beneﬁt people who  inject
rugs. The US$ 430 million ﬁgure also excludes additional activ-
ties and budgets that are possibly directed toward people who
nject drugs through tuberculosis and health system strengthening
rants.
Around US$ 120 million was budgeted for activities beyond the
comprehensive package”—including development of supportive
nvironments (US$ 15.1 million), training and capacity building
US$ 9.9 million), and monitoring and evaluation (US$ 17.5 million).
hese interventions remain integral despite their omission from the
nited Nations package: the International HIV/AIDS Alliance, for Drug Policy 23 (2012) 279– 285 283
example, has outlined 15 interventions that form a “harm reduc-
tion approach” (International HIV/AIDS Alliance, 2010). Fourteen
percent of the budgeted funding was  allocated to programme over-
heads including stafﬁng, building costs, administration and grant
management. This is higher than expected and may reﬂect high
start-up costs for these interventions in many settings.
Notably, US$ 5.1 million was budgeted for activities within
drug detention centres in Cambodia, China and Viet Nam. These
compulsory, extrajudicial centres are often run by police or the
military, and their existence raises major public health and human
rights concerns (Global Fund, 2011f)—with reports of forced labour,
coerced treatment and torture (Human Rights Watch, 2010). The
Global Fund and partners have repeatedly called for these centres
to close (Kazatchkine, 2010). Since these grants were approved, the
Global Fund has worked closely with the relevant Country Coordi-
nating Mechanisms and programme implementers to remove these
activities from grant budgets and workplans—ensuring that Global
Fund funding does not support the operation of these centres nor
legitimise their existence.
Between  Rounds 1 and 9, the Global Fund approved US$ 10.8
billion for HIV grants (Global Fund, 2010b). The US$ 430 million
identiﬁed in this analysis therefore represents around 4 percent of
this total approved funding. This is a higher percentage than found
in earlier analyses (Atun & Kazatchkine, 2010; Global Fund, 2010a)
which may  reﬂect an increasing level of investments, helped also
by the more detailed methodology used for this study. Nonethe-
less, there is clear evidence that the global resource needs for harm
reduction are not being met  by the current funding available from
all sources (Mathers et al., 2010; Stimson et al., 2010). Recent mod-
elling for the UNAIDS Strategic Investment Framework showed that
US$ 2.3 billion will be needed in 2015 to deliver harm reduction
at levels that can impact upon the epidemic—compared to the US$
0.5 billion currently estimated to be available (Schwartländer et al.,
2011). In 2007, it was estimated that just US$ 160 million of domes-
tic and international funding was  spent on harm reduction – less
than US$ 13 per person who  injects drugs – with more than 25 per-
cent coming from the Global Fund (Stimson et al., 2010). In 2009, a
study commissioned by the United Nations Regional Task Force on
Injecting Drug Use and HIV/AIDS for Asia and the Paciﬁc found that
only around 10 percent of the resource needs for harm reduction
in the region were being met  (Bergenstrom et al., 2010).
In  2010, UNAIDS identiﬁed 20 target countries for “intensive
and comprehensive support” based on their epidemiological con-
texts: Afghanistan, Bangladesh, Belarus, China, India, Indonesia,
Kazakhstan, Kenya, Kyrgyzstan, Lithuania, Mauritius, Moldova
(Republic), Myanmar, Nepal, Nigeria, Pakistan, South Africa, Tan-
zania (United Republic), Ukraine and Viet Nam (UNAIDS, 2010). Of
these, all but two are included in this analysis – the exceptions
being Lithuania (which is ineligible for Global Fund support) and
South Africa.
In  Round 10 (2010), the Global Fund created a dedicated funding
reserve for HIV proposals that focus on most-at-risk populations.
This should further boost investments in harm reduction. Although
many of the Round 10 grants were still being negotiated at the time
of the study, nearly half of the approved HIV proposals contained
activities for people who  use drugs. These include the ﬁrst Global
Fund proposal from Malaysia, new programmes planned in Kenya,
and a multicountry proposal from the Middle East and North Africa
Harm Reduction Association (MENAHRA) to support advocacy and
capacity building in 13 countries.
However, in November 2011 the Global Fund Board took the
decision to replace Round 11 with a ‘Transitional Funding Mech-
anism’. Against a backdrop of economic uncertainty, this new
mechanism allows for the continuation (but not the further scale-
up) of “essential” services that face disruption between 2012 and
2014 (for example, due to an existing grant ending). Although the
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lobal Fund has included “[HIV] prevention and treatment targeted
t. . . people who inject drugs” as an example of the “essential”
ervices to be continued (Global Fund, 2011g), the impact of this
ecision – and the broader ﬁnancial constraints being experienced
lobally – remains to be seen.
imitations
This  study has some notable limitations. The analysis only
ncludes HIV grants, omitting possible investments in people who
nject drugs through tuberculosis and health system strengthening
rants. It also does not include grants that were approved in Round
0 (2010), as many of these were still being negotiated at the time
f the study. This means that the US$ 430 million budgeted and
rojected investment for people who inject drugs likely underesti-
ates the true total that has been invested since the inception of
he Global Fund in 2002. Future research should review new grants
rom Round 10 and beyond to assess ongoing trends over time.
For  grants that were still in Phase 1 (or the ﬁrst period of their
olling Continuation) at the end of 2011, projections were made for
heir remaining years of implementation. This approach assumed
hat these grants will remain active for their full lifetime. The
erformance-based funding matrix used for the projections reﬂects
he decision-making process at the Global Fund, but grant budgets
an be revised during reviews and this is something that cannot be
eliably predicted. Future analysis should replace these projections
ith data from new detailed budgets once they are available.
In  addition, budget lines that focus on multiple most-at-risk
opulations were divided between the target groups. This method-
logy has been used in previous Global Fund portfolio analyses,
ut assumes that an equal number of individuals from each tar-
et group will beneﬁt from the activity. Although this scenario is
nlikely, it remains the most time-effective method available for
ssessing these multiple population budget lines.
Finally, the study did not look at unit costs being paid, nor varia-
ions in costs for core harm reduction products between countries
such as needles, syringes, methadone and buprenorphine). There
ave been numerous studies demonstrating the cost-effectiveness
f harm reduction—such as a major study from Australia which
howed that needle and syringe programmes returned AU$4 in
irect health care cost savings for every AU$1 invested (Australian
overnment, 2009). Future analyses should explore returns on
nvestment, the numbers of people reached by these grants, and
ross-country cost comparisons to help programmes determine if
hey are overspending on key products. Further studies could also
nalyse the proposals that were not approved by the Global Fund
oard, and assess the quality of the interventions that are being
unded.
onclusions
In conclusion, this study represents the most comprehensive
ssessment of Global Fund investments in harm reduction to date.
t demonstrates that the Global Fund is a major donor for ser-
ices targeting people who inject drugs—with an estimated US$
30 million budgeted or projected for grants in Rounds 1 (2002) to
 (2009). Two-thirds of this money was allocated for the “compre-
ensive package” of interventions as deﬁned by WHO, UNAIDS and
NODC.
Nonetheless, more than half of the countries with approved HIV
roposals between Rounds 1 and 9 did not include harm reduc-
ion activities in their budgets. The investments currently available
hrough the Global Fund, other international donors and domes-
ic sources fall short of the estimated needs for this population. In
rder to reach the recently agreed target of “reducing transmission Drug Policy 23 (2012) 279– 285
of  HIV among people who inject drugs by 50 percent by 2015” (UN
General Assembly, 2011), countries should continue to apply for
interventions addressing people who  inject drugs, basing their pro-
posals on the evidence-based guidance from the Global Fund and
partners.
Resource tracking exercises such as this, coupled with an
estimation of resource needs and gaps, are critical to inform
advocacy and ﬁnancing decisions. These should be continued by
the Global Fund and others—not least to assess the impact of the
current global economic downturn on HIV responses for this key
population.
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